Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... DALLAS , July 2, 2015 ... Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial ... Trends & Global Forecast to 2020", published by MarketsandMarkets, the ... and is projected to reach $6.20 Billion by 2020, at ... Browse 8 4 market ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has announced the ... by Application - Forecast to 2020" report to their offering. ... $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, ... dominated by North America , followed by ... of the World (RoW). The cancer diagnostics market in ...
(Date:7/2/2015)... SAN FRANCISCO , July 2, 2015  The ... www.tryloud.com ), the world,s first HIPAA compliant mobile app ... delivery of farm-to-table fresh medical marijuana, announced today that ... Unlike Eaze, Meadow and more than half ... in the last year, Loud Cannabis is unique in ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
... 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, XSSE: OXGN), a ... and eye,diseases, announced today the publication of two ... afternoon at the,Annual Meeting of the American Society ... abstract reports for the first time full data ...
... June 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated ... trial showing that tanespimycin demonstrated antitumor,activity and ... patient with a BRAF mutation (V600E) who ... initiation) and while on,tanespimycin demonstrated progression-free survival ...
Cached Medicine Technology:OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4
(Date:7/2/2015)... ... ... realized that the gift of poetry was fully in him, as beautiful phrases riddled his ... years later he was publishing an entire book of poetry. He knew there was something ... believed that the best way to lift yourself up, is in the effort of lifting ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of his 80th birthday, ... raise awareness and money for the Pulmonary Hypertension Association (PHA). Stevenson began the ... near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning and is making ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... of Dr. Divakar R. Krishnareddy, M.D., to the orthopedic and spine surgery team ... disc herniations, sprains, strains, bursitis, and tendonitis. Along with the spine and spine ...
(Date:7/2/2015)... ... 02, 2015 , ... Octo Consulting Group, (Octo), a leading ... has announced they are among nine contractors awarded the U.S. Securities and Exchange ... not to exceed $250 million. , To achieve the goals of the ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... healthcare providers, has been retained to lead a national chief executive officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
Breaking Medicine News(10 mins):Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3
... , , WAYNE, Pa., Aug. 20 Forty-nine ... a 2009 Spine Technology Award. The entry deadline was August 15. ... eligible to enter. , , The Spine Technology ... bring increased recognition to exemplary and innovative spine surgery products and ...
... release is available in German . , ... has investigated the reliability of diagnosing bronchial asthma in children ... the test results can have for these patients. IQWiG published ... the available studies do not reveal any diagnostic procedure to ...
... blood test can now be used to detect brain damage ... even after a two-month break from boxing. This is shown ... University of Gothenburg, Sweden. The results of the ... Erciyes University Medical School in Turkey are published in the ...
... time, it has been shown that patients who receive ... who receive kidney transplants from deceased donors. ... patients compared to kidney transplant recipients," published in the ... a total of 1,239 patients were followed for up ...
... , , , , , ... at 1:30pm at the Rouses Market, 4500 Tchoupitoulas Street , ... and R o uses Markets, the largest independent ... ealthy , www.cho o ...
... different scents, the nose detects them individually, study finds ... might know -- but sometimes one nostril detects scents ... Researchers say that subtle disparities in perception result from ... smell arriving at one nostril or the other. They ...
Cached Medicine News:Health News:49 Companies Submit Products for First Spine Technology Awards; Entries Now Closed 2Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 2Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 3Health News:Reliability and benefit of diagnostic procedure for asthma in young children is unclear 4Health News:Blood test can detect brain damage in amateur boxers 2Health News:Night home hemodialysis shown to be as good as transplant in treating kidney failure 2Health News:Ochsner and Rouses Markets Partner for Choose Healthy Initiative 2Health News:Ochsner and Rouses Markets Partner for Choose Healthy Initiative 3Health News:Nostrils Compete to Relay Key Fragrance 2
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... BRO-YP2 is Fujinon's pediatric ... outside diameter allows for ... The standard 2.0mm channel ... accessory passage in all ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Medicine Products: